Retatrutide FDA Approval Timeline: When Will Retatrutide Be Available?

Where Retatrutide Stands Today (March 2026)

Retatrutide (LY3437943) is currently in Phase 3 clinical development under Eli Lilly’s TRIUMPH program. It is not approved for any indication in any country. No New Drug Application (NDA) has been filed with the FDA or any other regulatory authority.

However, significant progress has been made since Phase 3 trials began. In December 2025, Eli Lilly announced results from TRIUMPH-4, the first Phase 3 trial in the retatrutide program to report data. The results were historic: -28.7% mean body weight reduction at the 12 mg dose over 68 weeks, the largest weight loss ever reported for any pharmaceutical agent in a Phase 3 clinical trial.

The drug completed Phase 2 trials with results published in the New England Journal of Medicine, demonstrating up to 24.2% body weight reduction at 48 weeks. These results prompted initiation of the multi-trial TRIUMPH Phase 3 program. Understanding when approval might occur requires examining the regulatory pathway step by step, without overstating the certainty of any timeline.

The TRIUMPH Phase 3 Program

Program Scope

Eli Lilly’s Phase 3 program for retatrutide is one of the largest metabolic drug development programs currently underway. It includes:

• TRIUMPH 1-7: Seven trials evaluating retatrutide for obesity and weight-related conditions across different populations and comorbidities
• TRANSCEND: A dedicated trial evaluating retatrutide for type 2 diabetes
• SYNERGY: A trial evaluating retatrutide for metabolic dysfunction-associated steatohepatitis (MASH), with histological endpoints

The program spans multiple countries, enrolls thousands of participants, and evaluates retatrutide across the full spectrum of metabolic disease — obesity, diabetes, and liver disease.

TRIUMPH-4: First Phase 3 Results

TRIUMPH-4 was specifically designed for adults with obesity and knee osteoarthritis. Key results announced in December 2025:

• Retatrutide 12 mg: -28.7% mean weight loss at 68 weeks
• Retatrutide 8 mg: -25.4% mean weight loss at 68 weeks
• 99% of participants at 12 mg achieved at least 5% weight loss
• 75% reduction in knee osteoarthritis pain scores (WOMAC)
• New safety signal: dysesthesia (abnormal sensory sensations) in 20.9% at 12 mg versus 0.7% placebo

These results validated the Phase 2 signal and provided strong efficacy evidence for regulatory submission. However, TRIUMPH-4 alone is unlikely to be sufficient for an NDA — the FDA typically requires data from multiple pivotal trials, and the dysesthesia signal will need characterization across the broader program.

Remaining Trial Readouts

As of March 2026, the following major readouts are still pending:

• TRIUMPH-1 (primary obesity pivotal trial): Expected to be the main efficacy trial for the obesity NDA. Results anticipated in late 2026 or early 2027.
• TRIUMPH-2 through TRIUMPH-7: Additional trials covering different patient populations, comorbidities, and treatment durations
• TRANSCEND (type 2 diabetes): Required for a diabetes indication
• SYNERGY (MASH): Required for a liver disease indication

Eli Lilly has not disclosed specific dates for all Phase 3 readouts, but public statements and analyst communications suggest additional results could become available throughout 2026 and 2027.

The Regulatory Pathway: Step by Step

Drug approval follows a well-established sequence, each step with its own typical duration:

Step 1: Phase 3 Data Collection and Readout (Current Stage)

Pivotal trials typically run 68-72 weeks for obesity indications. Including enrollment time, data collection, and analysis, the interval from Phase 3 initiation to primary data readout is generally 2-3 years. TRIUMPH-4 has reported, and initial results from other TRIUMPH trials are anticipated in late 2026 to 2027.

Step 2: NDA Preparation and Submission

After positive Phase 3 results, the sponsor compiles the complete data package into a New Drug Application. This process typically takes 6-12 months after the primary data readout, though some sponsors begin preparing the NDA in parallel with late-stage data collection (a strategy called “rolling submission”).

For the obesity indication, Eli Lilly will need to compile data from TRIUMPH-4 and at least one additional pivotal obesity trial, along with the complete safety database from across the TRIUMPH program. An NDA filing is most likely in late 2027 or 2028.

Step 3: FDA Review

Once an NDA is accepted for review, the FDA standard review period is 10-12 months. Priority Review designation, if granted, shortens this to approximately 6-8 months.

• Standard Review: 10-12 months from NDA acceptance
• Priority Review: 6-8 months from NDA acceptance

Priority Review is granted when a drug offers a significant improvement over available therapy for a serious condition. Given the magnitude of retatrutide’s weight loss and the potential MASLD benefit, Priority Review is plausible but not guaranteed.

Step 4: Advisory Committee Meeting

The FDA may convene an advisory committee (AdCom) of independent experts to evaluate the application. This is not always required but is common for novel mechanisms. The advisory committee reviews efficacy data, safety concerns (including the dysesthesia signal), and the overall benefit-risk profile. The AdCom provides a recommendation, but the FDA is not bound by it.

Step 5: FDA Decision (PDUFA Date)

The FDA sets a target action date (the PDUFA date) when it commits to completing its review. The agency will either approve the drug, issue a Complete Response Letter requesting additional information, or (rarely) deny approval outright.

Realistic Timeline Estimates

Optimistic Scenario (Late 2027)

This scenario assumes:

• Multiple TRIUMPH readouts complete by mid-2027
• Rolling NDA submission begins in parallel with late trial readouts
• Priority Review designation is granted
• No major safety signals beyond dysesthesia, which is adequately characterized
• Clean FDA review with no major information requests

Base Case Scenario (2028)

This is the most likely timeline:

• TRIUMPH program substantially complete by late 2027
• NDA submitted in late 2027 or early 2028
• Standard or Priority Review (10-12 months or 6-8 months)
• FDA approval in late 2028

Delayed Scenario (2029 or Later)

Possible if:

• Dysesthesia signal requires additional safety studies
• FDA requests a cardiovascular outcomes trial before approval
• Manufacturing or supply chain issues delay submission
• Enrollment delays push trial readouts later than expected

How This Compares to Tirzepatide and Semaglutide

Examining the timelines of recently approved metabolic drugs provides useful context:

Semaglutide (Wegovy)

Novo Nordisk published the STEP 1 Phase 3 obesity results in February 2021. The FDA approved Wegovy in June 2021 — an unusually fast turnaround enabled by prior approval of semaglutide for diabetes (Ozempic) and rolling NDA submission. The total development time from first-in-human to obesity approval was approximately 6 years.

Tirzepatide (Zepbound)

Eli Lilly published the SURMOUNT-1 Phase 3 obesity data in mid-2022. Zepbound received FDA approval for obesity in November 2023, approximately 17 months later. This was expedited by prior diabetes approval (Mounjaro in May 2022), which established the safety database and manufacturing infrastructure.

Retatrutide: Key Difference

A critical difference for retatrutide is that it does not yet have approval in any indication. Without a prior diabetes approval to build upon, the first retatrutide approval may take somewhat longer than the obesity approvals for semaglutide and tirzepatide. The FDA will need to evaluate the entire safety database from scratch, including the novel glucagon receptor component and the dysesthesia signal.

Potential for Expedited Pathways

Several factors could accelerate retatrutide’s path:

• Breakthrough Therapy Designation: If the FDA determines that retatrutide may offer substantial improvement over existing treatments, this designation provides more intensive FDA guidance, organizational commitment, and potentially faster review. The -28.7% weight loss in TRIUMPH-4 and the unique triple receptor mechanism could support such a designation.
• Rolling submission: Eli Lilly could submit sections of the NDA as they are completed rather than waiting for the complete package, reducing the gap between data readout and submission acceptance.
• Priority Review: Possible given the significant unmet need, particularly for MASLD where approved treatments are limited.
• Accelerated Approval (for MASH): If SYNERGY demonstrates histological improvement, an accelerated approval pathway for the MASH indication could be explored, though this would likely be separate from the obesity filing.

Multiple Indications, Multiple Timelines

Different indications will likely follow different regulatory timelines:

• Obesity: Most likely the first indication, given commercial precedent and regulatory familiarity with weight management approvals. Estimated approval: late 2027-2028.
• Type 2 diabetes: Could follow closely after the obesity approval, using the TRANSCEND data. Estimated approval: 2028-2029.
• MASH: May require longer trials with histological endpoints and faces a less established regulatory pathway. The SYNERGY trial could support approval, but timing depends on study duration and regulatory requirements. Estimated approval: 2029 or later.

Latest Milestones as of March 2026

What Needs to Happen Before Approval

For patients wondering “when will retatrutide be available,” here is what must still occur:

1. Remaining Phase 3 trials must report results: TRIUMPH-4 alone is not sufficient for an NDA. At minimum, the primary obesity pivotal trial must be completed.
2. Safety database must be compiled: The FDA requires a comprehensive safety analysis across all trials.
3. Dysesthesia must be characterized: The 20.9% incidence in TRIUMPH-4 needs context from other trials.
4. NDA must be prepared and submitted: This includes manufacturing data, labeling proposals, and the complete clinical dataset.
5. FDA must complete its review: 6-12 months depending on review pathway.
6. Manufacturing must be scaled: Commercial-scale production of retatrutide must be established and validated.

Frequently Asked Questions About Retatrutide Approval

When will retatrutide be approved?

The most realistic estimate for FDA approval is 2028, though an optimistic scenario could see approval in late 2027. This assumes positive Phase 3 results, timely NDA submission, and no major regulatory delays. The timeline is subject to change.

Has Eli Lilly filed for FDA approval of retatrutide?

No. As of March 2026, no NDA or BLA has been filed with the FDA for retatrutide. The TRIUMPH Phase 3 program is still ongoing, and Eli Lilly needs data from additional pivotal trials before filing.

Will retatrutide get Priority Review from the FDA?

It is possible but not guaranteed. Priority Review is granted when a drug offers significant improvement over available therapy for a serious condition. Retatrutide’s -28.7% weight loss in TRIUMPH-4 and its unique triple receptor mechanism could support a Priority Review designation, which would shorten the FDA review period from 10-12 months to 6-8 months.

Can I get retatrutide through a clinical trial?

Yes, clinical trial enrollment is the only legitimate way to access retatrutide. Visit ClinicalTrials.gov and search for “retatrutide” or “LY3437943” to find active trials. Eligibility criteria vary by trial, and participants may be randomized to placebo.

Why is drug approval so slow?

The FDA approval process is designed to ensure that medications are both safe and effective before being made available to the public. Phase 3 trials must enroll thousands of participants, treat them for extended periods (often 68+ weeks), collect and analyze data, and demonstrate an acceptable benefit-risk profile. This process protects patients but inherently takes time — typically 2-3 years for Phase 3 alone, followed by 6-12 months of FDA review.

What Patients and Clinicians Should Know

The most important message is that retatrutide is not yet available and will not be for at least 1-2 years. Patients should:

• Work with their healthcare providers on currently approved treatment options (Wegovy, Zepbound, etc.)
• Not purchase unregulated “retatrutide” from online sources — these products are not FDA-approved, not quality-controlled, and potentially dangerous
• Consider clinical trial enrollment as the only legitimate route to access retatrutide, via ClinicalTrials.gov
• Monitor Eli Lilly’s public announcements for Phase 3 data updates

Timelines in drug development are inherently uncertain. The estimates provided here are based on typical regulatory patterns and publicly available information, but actual events may diverge significantly in either direction.

Key Takeaways

• Current status: Retatrutide is in Phase 3 (TRIUMPH program), with TRIUMPH-4 results published in December 2025
• Not approved: No regulatory authority has approved retatrutide for any indication
• No NDA filed: Eli Lilly has not yet submitted a regulatory application
• TRIUMPH-4 results: -28.7% weight loss at 12 mg, the largest ever in a Phase 3 obesity trial
• Remaining steps: Additional Phase 3 readouts, NDA preparation, FDA review, and potential advisory committee
• Best estimate for approval: 2028 (base case), late 2027 (optimistic)
• How to access now: Clinical trials only, via ClinicalTrials.gov
• Warning: Avoid unregulated online sources claiming to sell retatrutide